Ampio Pharmaceuticals (AMPE) 10-Q 8 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 08, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'AMPE	'
Entity Registrant Name	'AMPIO PHARMACEUTICALS, INC.	'
Entity Central Index Key	'0001411906	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	51,972,266

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current assets	'	'
Cash and cash equivalents	$65,635,267	$26,309,449
Prepaid expenses	1,152,934	131,986
Prepaid research and development - related party (Note 9)	265,785	'
Total current assets	67,053,986	26,441,435
Fixed assets, net (Note 2)	8,687,592	1,298,504
In-process research and development	7,500,000	7,500,000
Patents, net	699,563	734,957
Long-term portion of prepaid research and development - related party (Note 9)	996,694	'
Deposits	43,856	43,856
Total noncurrent assets	17,927,705	9,577,317
Total assets	84,981,691	36,018,752
Current liabilities	'	'
Accounts payable	3,637,150	1,900,576
Accrued liabilities - related party (Note 9)	450,000	'
Accrued bonuses	37,054	522,056
Deferred rent	79,105	'
Deferred revenue	85,714	50,000
Total current liabilities	4,289,023	2,472,632
Long-term deferred revenue	511,607	331,250
Long-term deferred rent	270,968	'
Total liabilities	5,071,598	2,803,882
Commitments and contingencies (Note 6)	'	'
Stockholders' equity	'	'
Preferred Stock, par value $.0001; 10,000,000 shares authorized; none issued	0	'
Common Stock, par value $.0001; 100,000,000 shares authorized; shares issued and outstanding - 51,937,431 in 2014 and 42,065,031 in 2013	5,194	4,207
Additional paid-in capital	163,041,438	96,942,744
Advances to stockholders	-90,640	-90,640
Accumulated Deficit	-82,712,858	-63,779,155
Total Ampio stockholders' equity	80,243,134	33,077,156
Non-controlling interests	-333,041	137,714
Total equity	79,910,093	33,214,870
Total liabilities and equity	$84,981,691	$36,018,752

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Statement Of Financial Position [Abstract]	'	'
Preferred Stock, par value	$0.00	$0.00
Preferred Stock, shares authorized	10,000,000	10,000,000
Preferred Stock, shares issued	'	'
Common Stock, par value	$0.00	$0.00
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	51,937,431	42,065,031
Common Stock, shares outstanding	51,937,431	42,065,031

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Statement [Abstract]	'	'	'	'
License revenue	$21,429	$12,500	$33,929	$25,000
Expenses	'	'	'	'
Research and development	5,567,559	4,736,950	13,361,967	7,062,168
Research and development - related party (Note 9)	66,446	'	77,521	'
General and administrative	3,327,625	1,732,592	6,009,899	3,505,996
Total operating expenses	8,961,630	6,469,542	19,449,387	10,568,164
Other income (expense)	'	'	'	'
Interest income	7,505	3,172	11,000	7,449
Derivative expense	0	-139,389	0	-265,867
Total other income (expense)	7,505	-136,217	11,000	-258,418
Net loss	-8,932,696	-6,593,259	-19,404,458	-10,801,582
Net loss applicable to non-controlling interests	241,176	175,638	470,755	205,333
Net loss applicable to Ampio	($8,691,520)	($6,417,621)	($18,933,703)	($10,596,249)
Weighted average number of Ampio common shares outstanding	51,917,528	37,090,989	48,453,144	37,081,800
Basic and diluted Ampio net loss per common share	($0.17)	($0.17)	($0.39)	($0.29)

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (USD $)	Total	Common Stock [Member]	Additional Paid in Capital [Member]	Advances to Stockholders [Member]	Accumulated Deficit [Member]	Non-controlling Interest [Member]
Beginning Balance at Dec. 31, 2013	$33,214,870	$4,207	$96,942,744	($90,640)	($63,779,155)	$137,714
Beginning Balance, shares at Dec. 31, 2013	'	42,065,031	'	'	'	'
Issuance of common stock for services	30,000	'	30,000	'	'	'
Issuance of common stock for services, shares	'	4,209	'	'	'	'
Issuance of common stock in exchange for cash in March 2014, net of offering costs of $4,999,777 (unaudited)	63,425,223	979	63,424,244	'	'	'
Issuance of common stock in exchange for cash, shares	'	9,775,000	'	'	'	'
Options exercised, net	17,553	8	17,545	'	'	'
Options exercised, net, shares	'	85,684	'	'	'	'
Warrants exercised, net	0	'	'	'	'	'
Warrants exercised, net, shares	'	7,507	'	'	'	'
Stock-based compensation	2,626,905	'	2,626,905	'	'	'
Stock-based compensation, shares	'	0	'	'	'	'
Net loss	-19,404,458	'	'	'	-18,933,703	-470,755
Ending Balance at Jun. 30, 2014	$79,910,093	$5,194	$163,041,438	($90,640)	($82,712,858)	($333,041)
Ending Balance, shares at Jun. 30, 2014	'	51,937,431	'	'	'	'

Consolidated_Statements_of_Sto1

Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical) (USD $)	6 Months Ended
	Jun. 30, 2014
Statement Of Stockholders Equity [Abstract]	'
Issuance of common stock in exchange for cash, offering costs	$4,999,777

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (Unaudited) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
			Luoxis Diagnostics [Member]	Luoxis Diagnostics [Member]
Cash flows from operating activities:	'	'	'	'
Net loss	($19,404,458)	($10,801,582)	'	'
Depreciation and amortization	83,075	57,759	'	'
Amortization of prepaid research and development - related party (Note 9)	77,521	'	'	'
Common stock issued for services	30,000	88,050	'	'
Stock-based compensation expense	2,626,905	1,370,803	'	'
Derivative expense	0	265,867	'	'
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'	'
(Increase) in prepaid expenses	-1,020,948	-249,487	'	'
(Increase) in prepaid research and development - related party (Note 9)	-1,340,000	'	'	'
Increase in accounts payable	198,671	557,912	'	'
Increase in accrued liabilities - related party (Note 9)	450,000	'	'	'
Increase in deferred rent	350,073	'	'	'
Increase (decrease) in deferred revenue	216,071	-25,000	'	'
(Decrease) in accrued bonuses	-485,002	'	'	'
Net cash used in operating activities	-18,218,092	-8,735,678	'	'
Cash flows used in investing activities:	'	'	'	'
Purchase of fixed assets	-5,898,866	-283,814	'	'
Purchase of patents	0	-330,000	'	'
Net cash (used in) investing activities	-5,898,866	-613,814	'	'
Cash flows from financing activities:	'	'	'	'
Proceeds from sale of common stock	68,442,553	143,519	0	4,652,500
Costs related to sale of common stock	-4,999,777	'	0	-672,210
Net cash provided by financing activities	63,442,776	4,123,809	'	'
Net change in cash and cash equivalents	39,325,818	-5,225,683	'	'
Cash and cash equivalents at beginning of period	26,309,449	17,682,517	'	'
Cash and cash equivalents at end of period	65,635,267	12,456,834	'	'
Non-cash transactions:	'	'	'	'
Issuance of Luoxis stock for patents	0	50,000	'	'
Warrant compensation from common stock offering costs	0	313,064	'	'
Debenture warrant exercise fair value adjustment	0	28,666	'	'
Fixed Assets included in accounts payable	$1,537,903	'	'	'

Basis_of_Presentation_Business

Basis of Presentation, Business and Mergers	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Basis of Presentation, Business and Mergers	'
	Note 1 – Basis of Presentation, Business and Mergers
	Basis of Presentation
	These unaudited financial statements represent the consolidated financial statements of Ampio Pharmaceuticals, Inc. (“Ampio” or “the Company”), formerly known as Chay Enterprises, Inc. (“Chay”), and its wholly-owned subsidiaries, DMI Life Sciences, Inc. (“Life Sciences”), DMI Acquisition Corp., DMI BioSciences, Inc. (“BioSciences”), Vyrix Pharmaceuticals, Inc. (“Vyrix”) and Luoxis Diagnostics, Inc. (“Luoxis”), a 80.9% owned subsidiary – see Note 3. These unaudited consolidated financial statements should be read in conjunction with Ampio’s Annual Report on Form 10-K for the year ended December 31, 2013, which included all disclosures required by generally accepted accounting principles. In the opinion of management, these unaudited consolidated financial statements contain all adjustments necessary to present fairly the financial position of Ampio and its subsidiaries on a consolidated basis and the consolidated results of operations and cash flows for the interim periods presented. The results of operations for the period ended June 30, 2014 are not necessarily indicative of expected operating results for the full year. The information presented throughout the document as of and for the period ended June 30, 2014 is unaudited. Ampio’s activities, being primarily research and development and raising capital, have not generated significant revenue to date.
	Newly Issued Accounting Pronouncements
	In June 2014, the FASB issued ASU 2014-10, “Development Stage Entities (Topic 915)”. The guidance eliminates the definition of a development stage entity thereby removing the incremental financial reporting requirements from U.S. GAAP for development stage entities, primarily presentation of inception to date financial statements. The provisions of the amendments are effective for Ampio’s calendar year 2015, however, early adoption is permitted and, accordingly, we have elected to implement the guidance in our second quarter 2014 financial statements.
	On May 28, 2014, the FASB issued ASU 2014-09 regarding ASC Topic 606, Revenue from Contracts with Customers. The standard provides principles for recognizing revenue for the transfer of promised goods or services to customers with the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance will be effective for our fiscal year beginning January 1, 2017. Early adoption is not permitted. We are currently evaluating the accounting, transition and disclosure requirements of the standard and cannot currently estimate the financial statement impact of adoption.
	Business
	We are a biopharmaceutical company focused on primarily developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depleting available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability. We are also focused on monetizing our sexual dysfunction portfolio and diagnostic platform.
	Mergers
	Life Sciences was incorporated in the state of Delaware on December 18, 2008 and did not conduct any business activity until April 16, 2009, at which time Life Sciences purchased certain assigned intellectual property (including 107 patents and pending patent applications), business products and tangible property from BioSciences. Life Sciences issued 3,500,000 shares of its common stock to BioSciences, and assumed certain liabilities, as consideration for the assets purchased. The assets that Life Sciences acquired from BioSciences had a carrying value of zero, as BioSciences had expensed all of the research and development costs it incurred with respect to the intellectual property purchased. On March 2, 2010, Life Sciences merged with Chay Acquisitions, a wholly-owned subsidiary of Chay Enterprises, Inc., a public company (the “Merger”). Chay issued 15,068,942 shares of common stock to acquire Life Sciences, which resulted in the stockholders of Life Sciences owning approximately 95.7% of Chay’s outstanding common stock after the consummation of the Merger and before taking into account the issuance of 1,325,000 additional shares of common stock. In conjunction with the Merger, Chay purchased 263,624 shares of its common stock from the Chay Control Shareholders for $150,000 in cash.
	As a result of the Merger, Life Sciences became a wholly-owned subsidiary of Chay. For accounting purposes, the Merger was treated as a reverse acquisition with Life Sciences as the acquirer and Chay as the acquired party. The business and financial information included in this report is the business and financial information of Life Sciences. The accumulated deficit of Chay has been included in additional paid-in capital. Subsequent to the Merger, Chay Enterprises, Inc. was renamed Ampio Pharmaceuticals, Inc.
	On March 23, 2011, Ampio acquired BioSciences (the “BioSciences Merger”). Biosciences’ principal asset consisted of the worldwide rights to Zertane, as to which BioSciences held 32 issued patents and 31 pending patent applications. Zertane is a repurposed drug to treat male sexual dysfunction pertaining to premature ejaculation (“PE”) in men.
	Error in Classification
	Patent costs were previously classified as research and development, however, it was determined that these costs were incorrectly classified and, therefore, have been reclassified as general and administrative expense for all periods presented. Patent costs consist of legal and filing fees related to obtaining and maintaining patents and should have been excluded from research and development activities as set forth in the Financial Accounting Standard Board’s Accounting Standards Codification topic 730, Research and Development. The impact of the correction of this error in classification decreased research and development expenses and correspondingly increased general and administrative expenses for the three months ended June 30, 2014 and 2013 by $662,397 and $512,246, respectively, and for the six months ended June 30, 2014 and 2013 by $1,271,656 and $973,850, respectively. The correction of this error had no impact on our total operating expenses or our net loss for any periods presented.

Fixed_Assets

Fixed Assets	6 Months Ended
	Jun. 30, 2014
Property Plant And Equipment [Abstract]	'
Fixed Assets	'
	Note 2 – Fixed Assets
	Fixed assets are recorded at cost and, once placed in service, are depreciated on the straight-line method over the estimated useful lives. Fixed assets consist of the following:
		As of			As of
		June 30, 2014			December 31, 2013
	Manufacturing Facility/Clean Room - in progress	$	8,318,299		$	1,000,843
	Office furniture and equipment		206,029			116,088
	Lab equipment		308,529			279,157
	Less accumulated depreciation		(145,265	)		(97,584	)
	Fixed assets, net	$	8,687,592		$	1,298,504

Formation_of_Subsidiaries

Formation of Subsidiaries	6 Months Ended
	Jun. 30, 2014
Text Block [Abstract]	'
Formation of Subsidiaries	'
	Note 3 – Formation of Subsidiaries
	On January 24, 2013, Ampio formed a wholly-owned subsidiary, Luoxis, to focus on the development and commercialization of the Oxidation Reduction Potential (“ORP”) technology platform. The ORP technology indicates disease severity and progression across a wide range of critical and chronic illnesses. Luoxis was funded through a private placement launched on February 15, 2013. On March 15, 2013, an initial closing was completed and two additional closings were completed on April 30 and May 31, 2013. A total of 4,652,500 shares were issued at $1.00 per share resulting in $4,652,500 of gross proceeds. Net proceeds were $3,980,290 after placement agent and legal fees. The placement agent also received 465,250 warrants to purchase Luoxis common stock valued at $313,064 in connection with the closing, which amount has been included in total offering costs in the consolidated statement of changes in stockholders’ equity (deficit). The warrants have a term of 5 years and an exercise price of $1.00. The warrants were issuable at the final closing and were exercisable one year thereafter. Concurrent with the March 15, 2013 closing, $330,000 was paid to Trauma Research LLC (“TRLLC”) and 50,000 shares of Luoxis common stock valued at $50,000 were issued to Institute for Molecular Medicine, Inc., both related parties, for assignment of all patents previously licensed by Ampio. The patents will be amortized over an overall estimated life of 15 years. As a result of the private placement closings, Ampio owns 80.9% of Luoxis. The consolidated financial statements include Luoxis since Ampio has a controlling financial interest and the third-party holdings (19.1%) are referred to as “non-controlling interests”.
	On November 18, 2013, Ampio formed Vyrix Pharmaceuticals, Inc., a wholly-owned subsidiary, to provide a platform to focus and monetize its sexual dysfunction portfolio. On April 16, 2014, Vyrix filed a Form S-1 with the Securities and Exchange Commission relating to a proposed initial public offering of Vyrix common stock which filing was amended on June 19, 2014. Vyrix has a prepaid balance of approximately $521,000 related to the potential offering costs which will be offset against future proceeds.

License_AgreementRevenue_Recog

License Agreement/Revenue Recognition	6 Months Ended
	Jun. 30, 2014
Text Block [Abstract]	'
License Agreement/Revenue Recognition	'
	Note 4 – License Agreement/Revenue Recognition
	During 2011, Ampio entered into a license, development and commercialization agreement with a major Korean pharmaceutical company which was assigned to Vyrix when it was formed in 2013. The agreement grants the pharmaceutical company exclusive rights to market Zertane in South Korea for the treatment of PE and for a combination drug to be developed, utilizing Zertane and an erectile dysfunction drug. Upon signing of the agreement, Ampio received a $500,000 upfront payment, the net proceeds of which were $417,500 after withholding of Korean tax. The upfront payment has been deferred and is being recognized as license revenue over a ten year period. Milestone payments of $3,200,000 may be earned and recognized contingent upon achievement of regulatory approvals and cumulative net sales targets, which may take several years. In addition, Ampio will earn a royalty based on 25% of net sales, as defined, if the royalty exceeds the transfer price of the Zertane product. No royalties have been earned to date.
	On April 9, 2014, Vyrix entered into a Distribution and License Agreement with a New Zealand-based health services supplier, whereby the supplier has exclusive rights to market, sell and distribute Zertane in Canada, the Republic of South Africa, certain countries in Sub-Saharan Africa, Colombia and Latin America. The Agreement expires on a country by country basis on the later of fifteen years after the first commercial sale of the product in that country or expiration of market exclusivity for Zertane in that country. Upon signing the Agreement, the supplier paid $250,000 to Vyrix and may make milestone payments aggregating up to $3,025,000 based upon achieving Canadian and South African product regulatory approval and achieving specific sales goals. The upfront payment has been deferred and is being recognized as license revenue over a seven year period. In addition, the Agreement provides that the supplier pay royalties based on sales volumes.

Derivative_Financial_Instrumen

Derivative Financial Instruments	6 Months Ended
	Jun. 30, 2014
Derivative Instruments And Hedging Activities Disclosure [Abstract]	'
Derivative Financial Instruments	'
	Note 5 – Derivative Financial Instruments
	Ampio issued senior convertible unsecured debentures and related warrants in five tranches between August 2010 and January 2011 (the “Senior Convertible Debentures”). On February 28, 2011, Ampio’s Senior Convertible Debentures were converted to 1,281,852 shares of common stock. The warrants associated with the derivative liability expired on December 31, 2013, however, all the warrants were exercised prior to expiration. During the three and six months ended June 2013, a charge of $139,389 and $265,867 respectively, resulted from the change in fair value of these derivative financial instruments.

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Note 6 – Commitments and Contingencies
	Commitments and contingencies are described below and summarized by the following table:
		Total		Remaining		2015		2016		2017		2018		Thereafter
				2014
	Manufacturing Facility/Clean Room - in progress	$	2,473,922	$	2,473,922	$	—	$	—	$	—	$	—	$	—
	Ampion supply agreement		11,475,000		1,275,000		2,550,000		2,550,000		2,550,000		2,550,000		—
	Clinical research and trial obligations		6,709,007		6,420,528		288,479		—		—		—		—
	Sponsored research agreement with related party		1,543,750		162,500		325,000		325,000		325,000		325,000		81,250
	Office lease		3,290,327		79,697		286,966		296,639		306,312		315,985		2,004,728
		$	25,492,006	$	10,411,647	$	3,450,445	$	3,171,639	$	3,181,312	$	3,190,985	$	2,085,978
	Manufacturing Facility/Clean Room – In Progress
	The manufacturing facility/clean room will provide commercial scale, FDA compliant, GMP manufacturing of Ampion, an advanced research and development laboratory as well as a sufficient office space to consolidate the core operations of the Company in a single facility.
	Ampion Supply Agreement
	In connection with the manufacturing facility/clean room, in October 2013, Ampio entered into a human serum albumin ingredient and purchase sale agreement with a total commitment of $11,475,000.
	Clinical Research Obligations
	In connection with upcoming clinical trials, Ampio has a remaining commitment of $2,074,297 on contracts related to the Ampion study drug and $4,634,710 remaining contract commitments related to the Optina study drug.
	Sponsored Research Agreement with Related Party
	Ampio entered into a Sponsored Research Agreement with TRLLC, a related party, in September 2009. Under the terms of the Sponsored Research Agreement, Ampio is to provide personnel and pay for leased equipment. The Sponsored Research Agreement may be terminated without cause by either party on 180 days’ notice. As further noted in Note 9 – Related Party Transactions, in March 2014, the Sponsored Research Agreement was extended through March 2019, including a “no termination” period through March 2017. In a subsequent Addendum, the parties also agreed to increase the equivalent value of the personnel provided by Ampio from $263,750 to $325,000 per year.
	Leases
	On May 20, 2011, Ampio entered into a non-cancellable operating lease for office space effective June 1, 2011, which expired July 2014. Commitments include the annual operating expense increase for 2014. On December 13, 2013, Ampio entered into a 125 month non-cancellable operating lease for new office space and the manufacturing facility effective May 1, 2014. The new lease has initial base rent of $23,376 per month, with the total base rent over the term of the lease of approximately $3.3 million. The company recognizes rental expense of the facility on a straight-line basis over the term of the lease. Differences between the straight-line net expenses on rent payments are classified as liabilities between current deferred rent and long-term deferred rent. Rent expense for the respective periods is as follows:
		Three Months Ended June 30,				Six Months Ended June 30,
		2014		2013		2014		2013
	Rent expense	$	92,183	$	29,118	$	122,136	$	58,678

Common_Stock

Common Stock	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
Common Stock	'
	Note 7 – Common Stock
	Capital Stock
	At June 30, 2014 and December 31, 2013, Ampio had 100,000,000 shares of common stock authorized with a par value of $0.0001 per share and 10,000,000 shares of preferred stock authorized with a par value of $0.0001 per share.
	Shelf Registration
	On September 30, 2011, Ampio filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission to register Ampio common stock and warrants in an aggregate amount of up to $80 million for offering from time to time. The registration statement also registered for possible resale up to one million shares of common stock to be sold by directors and management (as selling shareholders) in future public offerings.
	On December 26, 2013, Ampio filed an additional shelf registration statement on Form S-3 with the Securities and Exchange Commission to register Ampio common stock and warrants in an aggregate amount of up to $100 million for offering from time to time in the future, as well as 1.5 million shares of common stock available for sale by selling shareholders. The shelf registration was declared effective on January 22, 2014 by the Securities and Exchange Commission.
	As a result of the equity raises subsequent to September 30, 2011, $60 million remains under the Form S-3 filed on December 26, 2013.
	Underwritten Public Offerings
	On March 5, 2014, Ampio completed an underwritten public offering for the sale of 9,775,000 shares of common stock at a price of $7.00 per share. Gross proceeds to the Company were $68,425,000 with net proceeds of $63,425,223 after underwriter fees and cash offering expenses.
	Registered Direct Placement
	On September 30, 2013, Ampio closed on the sale of 4,600,319 shares of common stock at $5.50 per share, for a total of $25,301,754 of gross proceeds and $25,003,986 net proceeds after offering costs. The sale of the common stock was made pursuant to the Form S-3 Shelf Registration.

Equity_Instruments

Equity Instruments	6 Months Ended
	Jun. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Equity Instruments	'
	Note 8 – Equity Instruments
	Options
	Ampio adopted a stock plan in March 2010. The number of shares of common stock reserved for issuance to officers, directors, employees and consultants through various means, including incentive stock options, non-qualified stock options, restricted stock grants, and other forms of equity equivalents is currently 11,700,000 shares.
	Ampio has computed the fair value of all options granted using the Black-Scholes option pricing model. In order to calculate the fair value of the options, certain assumptions are made regarding components of the model, including the estimated fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to valuation. Ampio estimated a volatility factor utilizing a weighted average of comparable published volatilities of peer companies. Ampio has estimated a forfeiture rate of zero as the effect of forfeitures has not been significant and the small number of option holders does not provide a reasonable basis for prediction. Ampio estimates the expected term based on the average of the vesting term and the contractual term of the options. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity. Ampio has computed the fair value of all options granted during the six months ended June 30, 2014 using the following assumptions:
	Expected volatility	72% - 85%
	Risk free interest rate	1.51% - 2.27%
	Expected term (years)	5.0 - 7.0
	Dividend yield	0%
	Ampio stock option activity is as follows:
		Number of			Weighted			Weighted Average			Aggregate Fair
		Options			Average			Remaining			Value
					Exercise Price			Contractual Life
	Outstanding December 31, 2013		5,135,058		$	3.54			8.74		$	10,273,070
	Granted		570,000		$	7.21
	Exercised		(107,504	)	$	1.57
	Forfeited/Cancelled		(34,792	)	$	3.42
	Outstanding June 30, 2014		5,562,762		$	3.62			7.74		$	12,411,628
	Exercisable at June 30, 2014		4,070,518		$	2.91			7.32		$	7,292,070
	Available for grant at June 30, 2014		4,796,092
	Pursuant to the Luoxis 2013 Stock Option Plan (the “2013 Plan”), 5,000,000 shares of its common stock were reserved for issuance under the 2013 Plan. On June 15, 2013, Luoxis granted 1,800,000 shares to officers, employees and consultants. The shares have an exercise price of $1.00 which is the same as the private placement offering price. Twenty-five percent of the shares vested immediately and the remainder vest annually on the grant date at a rate of 25% over the next three years. The fair value of these options totaling $1,272,366 were also calculated using the Black-Scholes option pricing model utilizing the same methodology as described above for Ampio. During the first quarter of 2014, Luoxis granted 150,000 options to officers and consultants. The options have an exercise price of $1.00 and the same vesting schedule as those granted on June 15, 2013. The fair value of these options totaling $101,242 were also calculated using the Black-Scholes option pricing model utilizing the same methodology as described above for Ampio including the following assumptions:
	Expected volatility	79% - 82%
	Risk free interest rate	0.75% - 1.38%
	Expected term (years)	5.0 - 6.5
	Dividend yield	0%
	Luoxis stock option activity is as follows:
		Number of			Exercise Price			Weighted Average			Aggregate Fair
		Options						Remaining			Value
								Contractual Life
	Outstanding December 31, 2013		1,800,000		$	1			9.72		$	1,272,366
	Granted		150,000		$	1
	Exercised		—		$	—
	Forfeited/Cancelled		—		$	—
	Outstanding June 30, 2014		1,950,000		$	1			9.01		$	1,373,607
	Exercisable at June 30, 2014		937,500		$	1			8.98		$	661,493
	Available for grant at June 30, 2014		3,050,000
	Vyrix has also adopted a 2013 Stock Option Plan (the “Vyrix 2013 Plan”) which reserved 5,000,000 shares of its common stock for issuance to officers, employees and consultants. As of June 30, 2014, 950,000 shares had been granted to a director, officers and consultants. Twenty-five percent or 237,500 shares vested immediately and the remainder vest annually over three years. On November 18, 2013, 500,000 of these shares were granted to the Vyrix Chief Executive Officer and the exercise price was to be based upon a future private equity offering. Management estimated a price of $1.75 per common share for valuing the option grant. The grant was valued utilizing the Black-Scholes option pricing model using the same methodology as described above for Ampio. The valuation resulted in a charge of $140,070 in the fourth quarter of 2013. In the first quarter of 2014, Vyrix engaged an independent third party consulting firm to perform a valuation which was completed and the stock price was set at $0.70 per share. All 950,000 options have been valued utilizing the $0.70 per share. As a result of the previous charge in the fourth quarter of 2013 and the revision of the exercise price, a reduction of stock compensation expense of $84,041 was reflected in the first quarter of 2014. Assumptions are as follows:
	Expected volatility	63% - 76%
	Risk free interest rate	0.90% - 2.02%
	Expected term (years)	5.0 - 6.5
	Dividend yield	0%
	Vyrix stock option activity is as follows:
		Number of			Exercise Price			Weighted Average			Aggregate Fair
		Options						Remaining			Value
								Contractual Life
	Outstanding December 31, 2013		500,000		$	1.75			9.94		$	557,134
	Granted		450,000		$	0.7
	Exercised		—		$	—
	Forfeited/Cancelled		—		$	—
	Outstanding June 30, 2014		950,000		$	0.7			9.54		$	416,369
	Exercisable at June 30, 2014		237,500		$	0.7			9.54		$	104,092
	Available for grant at June 30, 2014		4,050,000
	Stock-based compensation expense related to the fair value of stock options was included in the consolidated statements of operations as research and development expenses and general and administrative expenses as set forth in the table below. Ampio and its subsidiaries determined the fair value as of the date of grant using the Black-Scholes option pricing model and expenses the fair value ratably over the vesting period.
	The following table summarizes stock-based compensation expense for the three and six months ended June 30, 2014 and 2013:
		Three Months Ended June 30,						Six Months Ended June 30,
		2014			2013			2014			2013
	Research and development expenses
	Stock options
	Ampio	$	399,266		$	223,680		$	1,037,698		$	378,371
	Luoxis		51,584			202,495			103,168			202,495
	Vyrix		8,454			—			37,605			—
	General and administrative expenses
	Common stock issued for services		—			—			30,000			88,050
	Stock options
Ampio		1,092,060			231,695			1,391,067			675,483
Luoxis		35,576			114,454			93,591			114,454
Vyrix		18,734			—			(36,224	)		—
	$	1,605,674		$	772,324		$	2,656,905		$	1,458,853
Unrecognized expense at June 30, 2014
Ampio	$	4,102,852
Luoxis	$	698,425
Vyrix	$	275,193
Weighted average remaining years to vest
Ampio		1.33
Luoxis		2.03
Vyrix		2.54
Warrants
Ampio issued warrants in conjunction with its Senior Convertible Debentures, 2011 Private Placements and an underwritten public offering. A summary of all Ampio warrants is as follows:
	Number of			Weighted			Weighted Average
	Warrants			Average			Remaining
				Exercise Price			Contractual Life
Outstanding December 31, 2013		527,690		$	2.93			2.44
Warrants exercised - Private/Registered Direct Placements		(11,261	)	$	(3.13	)
Warrants exercised - Private/Registered Direct Placements		(100	)	$	(4.06	)
Outstanding June 30, 2014		516,329		$	3.26			1.94
The exercise price of the warrants associated with the Senior Convertible Debentures was fixed at $1.75 per share and the warrants expired on December 31, 2013. All of the warrants were exercised prior to expiration. Warrants issued in connection with the 2011 Private Placements are at $3.125 per share and expire March 31, 2016.
In connection with the final closing of the Luoxis private placement in May 2013, Luoxis issued warrants to purchase 465,250 shares of common stock at a price of $1.00 exercisable one year after the final closing. The weighted average remaining contractual life is 3.92 years. These warrants were valued using the Black-Scholes option pricing model. In order to calculate the fair value of the warrants, certain assumptions were made regarding components of the model, including the closing price of the underlying common stock, risk-free interest rate, volatility, expected dividend yield, and expected life. Changes to the assumptions could cause significant adjustments to valuation. The Company estimated a volatility factor utilizing a weighted average of comparable published volatilities of peer companies. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity. The offering costs and the additional paid-in capital for the warrants associated with the common stock offering was valued at $313,064 using the Black-Scholes valuation methodology because that model embodies all of the relevant assumptions that address the features underlying these instruments. Significant assumptions in valuing the Luoxis warrants were as follows:
Expected volatility		87	%
Risk free interest rate		0.52	%
Expected term (years)		5
Dividend yield		0	%

Related_Party_Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	Note 9 – Related Party Transactions
	Ampio has a sponsored research agreement with TRLLC, an entity controlled by our director and Chief Scientific Officer, Dr. Bar-Or. Under the terms of the research agreement, Ampio is to provide personnel and equipment with an equivalent value of $263,750 per year and to make monthly equipment lease payments of $7,236 on behalf of TRLLC. Lease commitments expired as of January 2011. In exchange, TRLLC will assign any intellectual property rights it develops on our behalf under the research agreement. The research agreement expires on August 31, 2014 and may be terminated by either party on six months’ notice or immediately if either party determines that the other is not fulfilling its obligations under the agreement.
	On March 17, 2014, Ampio, Luoxis and TRLLC entered into an Addendum to the research agreement to extend the termination date through March 31, 2019, including a “no termination” period through March 31, 2017, and to significantly modify and expand the research activities for Ampio and Luoxis in support of their business plans. In exchange for TRLLC extending the terms of the research agreement and for the expanded services, Ampio and Luoxis agreed to prepay TRLLC in the aggregate amounts of $725,000 and $615,000, respectively, during 2014. A total of $890,000 was paid in the first six months of 2014 and the remaining balance is due as follows: $300,000 and $150,000 in 2014 quarters three and four, respectively. The total prepaid of $1,340,000 is being amortized over the contract term of 60.5 months and is split between current and long-term on the balance sheet. In a subsequent addendum, the parties also agreed to increase the equivalent value of the personnel provided by Ampio from $263,750 to $325,000 per year.
	In June 2013, Luoxis entered into an agreement with TRLLC, a related party controlled by Dr. David Bar-Or, a director and officer of Ampio. The agreement provides for Luoxis to pay $5,834 per month to TRLLC in consideration for services related to research and development of Luoxis’ Oxidation Reduction Potential platform. In September 2013, Luoxis entered into an addendum to the agreement which provides for Luoxis to pay an additional $2,000 per month. These agreements are cancellable upon thirty days’ notice.
	Ampio had license agreements with the Institute for Molecular Medicine, Inc. (“IMM”), a nonprofit research organization founded by an officer and director of Ampio who also serves as IMM’s executive director. The license agreements were assigned to Life Sciences as a part of the asset purchase from BioSciences. Under the license agreements, Ampio paid the costs associated with maintaining intellectual property subject to the license agreements. As further noted in Note 3, the intellectual property associated with the license agreements was assigned to Luoxis.
	Immediately prior to the Merger on March 2, 2010, Chay accepted subscriptions for an aggregate of 1,325,000 shares of common stock from six officers and employees of Life Sciences, for a purchase price of $150,183. The purchase price was advanced to the six officers and employees by Chay at the time the subscriptions were accepted. These shares were issued immediately before the closing of the Merger but after the shareholders of Chay had approved the merger. The advances are non-interest bearing and due on demand and are classified as a reduction to stockholders’ equity. During the year ended December 31, 2011, one advance of $22,660 was repaid. During the three months ended March 31, 2012 an additional repayment of $36,883 was received.

Litigation

Litigation	6 Months Ended
	Jun. 30, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Litigation	'
	Note 10 – Litigation
	On August 30, 2013, Ampio was notified of a civil complaint filed against the Company and certain of its directors and executive officers as defendants. The Complaint alleges that the defendants breached a contract with the plaintiff for consulting services the plaintiff purportedly provided during two time periods: between November 2009 and February 2010 in connection with a proposed reverse merger transaction, and between mid-2010 and 2012. They also assert claims for promissory estoppel, unjust enrichment and fraudulent inducement and concealment. In July 2014, the plaintiff dismissed all claims against Dr. David Bar-Or with prejudice. The Company believes these claims are without merit and intends to defend this lawsuit vigorously. We believe the likelihood of a loss contingency related to this matter is remote and, therefore, no provision for a loss contingency is required.

Subsequent_Events

Subsequent Events	6 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	Note 11 – Subsequent Events
	On July 16, 2014, Luoxis granted 885,000 options to employees and advisors. During the third quarter of 2014, Luoxis engaged an independent third party consulting firm to perform a valuation which was completed and the stock price was set at $1.60 per share. All 885,000 options have an exercise price of $1.60 per share and have been valued utilizing this price.
	On July 22, 2014, Ampio moved into its new headquarters, manufacturing and research facility.
	On August 5, 2014, we announced the one month results of the open label portion of the MULTIPLE INJECTIONS STUDY of Ampion™ into the knees of patients with osteoarthritis (OA). During the study, we saw no serious drug related adverse events. We saw the pain and function scores improve compared to the SPRING study at the same time point. The study also includes serial high resolution MRI’s at various time points that will explore whether there are clinical benefits beyond pain relief.

Basis_of_Presentation_Business1

Basis of Presentation, Business and Mergers (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	These unaudited financial statements represent the consolidated financial statements of Ampio Pharmaceuticals, Inc. (“Ampio” or “the Company”), formerly known as Chay Enterprises, Inc. (“Chay”), and its wholly-owned subsidiaries, DMI Life Sciences, Inc. (“Life Sciences”), DMI Acquisition Corp., DMI BioSciences, Inc. (“BioSciences”), Vyrix Pharmaceuticals, Inc. (“Vyrix”) and Luoxis Diagnostics, Inc. (“Luoxis”), a 80.9% owned subsidiary – see Note 3. These unaudited consolidated financial statements should be read in conjunction with Ampio’s Annual Report on Form 10-K for the year ended December 31, 2013, which included all disclosures required by generally accepted accounting principles. In the opinion of management, these unaudited consolidated financial statements contain all adjustments necessary to present fairly the financial position of Ampio and its subsidiaries on a consolidated basis and the consolidated results of operations and cash flows for the interim periods presented. The results of operations for the period ended June 30, 2014 are not necessarily indicative of expected operating results for the full year. The information presented throughout the document as of and for the period ended June 30, 2014 is unaudited. Ampio’s activities, being primarily research and development and raising capital, have not generated significant revenue to date.
Newly Issued Accounting Pronouncements	'
	Newly Issued Accounting Pronouncements
	In June 2014, the FASB issued ASU 2014-10, “Development Stage Entities (Topic 915)”. The guidance eliminates the definition of a development stage entity thereby removing the incremental financial reporting requirements from U.S. GAAP for development stage entities, primarily presentation of inception to date financial statements. The provisions of the amendments are effective for Ampio’s calendar year 2015, however, early adoption is permitted and, accordingly, we have elected to implement the guidance in our second quarter 2014 financial statements.
	On May 28, 2014, the FASB issued ASU 2014-09 regarding ASC Topic 606, Revenue from Contracts with Customers. The standard provides principles for recognizing revenue for the transfer of promised goods or services to customers with the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance will be effective for our fiscal year beginning January 1, 2017. Early adoption is not permitted. We are currently evaluating the accounting, transition and disclosure requirements of the standard and cannot currently estimate the financial statement impact of adoption.
Business	'
	Business
	We are a biopharmaceutical company focused on primarily developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depleting available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability. We are also focused on monetizing our sexual dysfunction portfolio and diagnostic platform.
Mergers	'
	Mergers
	Life Sciences was incorporated in the state of Delaware on December 18, 2008 and did not conduct any business activity until April 16, 2009, at which time Life Sciences purchased certain assigned intellectual property (including 107 patents and pending patent applications), business products and tangible property from BioSciences. Life Sciences issued 3,500,000 shares of its common stock to BioSciences, and assumed certain liabilities, as consideration for the assets purchased. The assets that Life Sciences acquired from BioSciences had a carrying value of zero, as BioSciences had expensed all of the research and development costs it incurred with respect to the intellectual property purchased. On March 2, 2010, Life Sciences merged with Chay Acquisitions, a wholly-owned subsidiary of Chay Enterprises, Inc., a public company (the “Merger”). Chay issued 15,068,942 shares of common stock to acquire Life Sciences, which resulted in the stockholders of Life Sciences owning approximately 95.7% of Chay’s outstanding common stock after the consummation of the Merger and before taking into account the issuance of 1,325,000 additional shares of common stock. In conjunction with the Merger, Chay purchased 263,624 shares of its common stock from the Chay Control Shareholders for $150,000 in cash.
	As a result of the Merger, Life Sciences became a wholly-owned subsidiary of Chay. For accounting purposes, the Merger was treated as a reverse acquisition with Life Sciences as the acquirer and Chay as the acquired party. The business and financial information included in this report is the business and financial information of Life Sciences. The accumulated deficit of Chay has been included in additional paid-in capital. Subsequent to the Merger, Chay Enterprises, Inc. was renamed Ampio Pharmaceuticals, Inc.
	On March 23, 2011, Ampio acquired BioSciences (the “BioSciences Merger”). Biosciences’ principal asset consisted of the worldwide rights to Zertane, as to which BioSciences held 32 issued patents and 31 pending patent applications. Zertane is a repurposed drug to treat male sexual dysfunction pertaining to premature ejaculation (“PE”) in men.
Error in Classification	'
	Error in Classification
	Patent costs were previously classified as research and development, however, it was determined that these costs were incorrectly classified and, therefore, have been reclassified as general and administrative expense for all periods presented. Patent costs consist of legal and filing fees related to obtaining and maintaining patents and should have been excluded from research and development activities as set forth in the Financial Accounting Standard Board’s Accounting Standards Codification topic 730, Research and Development. The impact of the correction of this error in classification decreased research and development expenses and correspondingly increased general and administrative expenses for the three months ended June 30, 2014 and 2013 by $662,397 and $512,246, respectively, and for the six months ended June 30, 2014 and 2013 by $1,271,656 and $973,850, respectively. The correction of this error had no impact on our total operating expenses or our net loss for any periods presented.

Fixed_Assets_Tables

Fixed Assets (Tables)	6 Months Ended
	Jun. 30, 2014
Property Plant And Equipment [Abstract]	'
Schedule of Fixed Assets	'
	Fixed assets consist of the following:
		As of			As of
		June 30, 2014			December 31, 2013
	Manufacturing Facility/Clean Room - in progress	$	8,318,299		$	1,000,843
	Office furniture and equipment		206,029			116,088
	Lab equipment		308,529			279,157
	Less accumulated depreciation		(145,265	)		(97,584	)
	Fixed assets, net	$	8,687,592		$	1,298,504

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Summary of Commitments and Contingencies	'
	Commitments and contingencies are described below and summarized by the following table:
		Total		Remaining		2015		2016		2017		2018		Thereafter
				2014
	Manufacturing Facility/Clean Room - in progress	$	2,473,922	$	2,473,922	$	—	$	—	$	—	$	—	$	—
	Ampion supply agreement		11,475,000		1,275,000		2,550,000		2,550,000		2,550,000		2,550,000		—
	Clinical research and trial obligations		6,709,007		6,420,528		288,479		—		—		—		—
	Sponsored research agreement with related party		1,543,750		162,500		325,000		325,000		325,000		325,000		81,250
	Office lease		3,290,327		79,697		286,966		296,639		306,312		315,985		2,004,728
		$	25,492,006	$	10,411,647	$	3,450,445	$	3,171,639	$	3,181,312	$	3,190,985	$	2,085,978
Rent Expense	'
	Rent expense for the respective periods is as follows:
		Three Months Ended June 30,				Six Months Ended June 30,
		2014		2013		2014		2013
	Rent expense	$	92,183	$	29,118	$	122,136	$	58,678

Equity_Instruments_Tables

Equity Instruments (Tables)	6 Months Ended
	Jun. 30, 2014
Assumptions Used in Computing Fair Value of All Options Granted	'
	Ampio has computed the fair value of all options granted during the six months ended June 30, 2014 using the following assumptions:
	Expected volatility	72% - 85%
	Risk free interest rate	1.51% - 2.27%
	Expected term (years)	5.0 - 7.0
	Dividend yield	0%
Summary of Stock-Based Compensation Expense	'
	The following table summarizes stock-based compensation expense for the three and six months ended June 30, 2014 and 2013:
		Three Months Ended June 30,						Six Months Ended June 30,
		2014			2013			2014			2013
	Research and development expenses
	Stock options
	Ampio	$	399,266		$	223,680		$	1,037,698		$	378,371
	Luoxis		51,584			202,495			103,168			202,495
	Vyrix		8,454			—			37,605			—
	General and administrative expenses
	Common stock issued for services		—			—			30,000			88,050
	Stock options
	Ampio		1,092,060			231,695			1,391,067			675,483
	Luoxis		35,576			114,454			93,591			114,454
	Vyrix		18,734			—			(36,224	)		—
		$	1,605,674		$	772,324		$	2,656,905		$	1,458,853
	Unrecognized expense at June 30, 2014
	Ampio	$	4,102,852
	Luoxis	$	698,425
	Vyrix	$	275,193
	Weighted average remaining years to vest
	Ampio		1.33
	Luoxis		2.03
	Vyrix		2.54
Warrants Issued in Conjunction with its Senior Convertible Debentures	'
	Ampio issued warrants in conjunction with its Senior Convertible Debentures, 2011 Private Placements and an underwritten public offering. A summary of all Ampio warrants is as follows:
		Number of			Weighted			Weighted Average
		Warrants			Average			Remaining
					Exercise Price			Contractual Life
	Outstanding December 31, 2013		527,690		$	2.93			2.44
	Warrants exercised - Private/Registered Direct Placements		(11,261	)	$	(3.13	)
	Warrants exercised - Private/Registered Direct Placements		(100	)	$	(4.06	)
	Outstanding June 30, 2014		516,329		$	3.26			1.94
Ampio [Member]	'
Stock Option Activity	'
	Ampio stock option activity is as follows:
		Number of			Weighted			Weighted Average			Aggregate Fair
		Options			Average			Remaining			Value
					Exercise Price			Contractual Life
	Outstanding December 31, 2013		5,135,058		$	3.54			8.74		$	10,273,070
	Granted		570,000		$	7.21
	Exercised		(107,504	)	$	1.57
	Forfeited/Cancelled		(34,792	)	$	3.42
	Outstanding June 30, 2014		5,562,762		$	3.62			7.74		$	12,411,628
	Exercisable at June 30, 2014		4,070,518		$	2.91			7.32		$	7,292,070
	Available for grant at June 30, 2014		4,796,092
Luoxis Diagnostics [Member]	'
Stock Option Activity	'
	Luoxis stock option activity is as follows:
		Number of			Exercise Price			Weighted Average			Aggregate Fair
		Options						Remaining			Value
								Contractual Life
	Outstanding December 31, 2013		1,800,000		$	1			9.72		$	1,272,366
	Granted		150,000		$	1
	Exercised		—		$	—
	Forfeited/Cancelled		—		$	—
	Outstanding June 30, 2014		1,950,000		$	1			9.01		$	1,373,607
	Exercisable at June 30, 2014		937,500		$	1			8.98		$	661,493
	Available for grant at June 30, 2014		3,050,000
Assumptions Used in Computing Fair Value of All Options Granted	'
	The fair value of these options totaling $101,242 were also calculated using the Black-Scholes option pricing model utilizing the same methodology as described above for Ampio including the following assumptions:
	Expected volatility	79% - 82%
	Risk free interest rate	0.75% - 1.38%
	Expected term (years)	5.0 - 6.5
	Dividend yield	0%
Significant Assumptions	'
	Significant assumptions in valuing the Luoxis warrants were as follows:
	Expected volatility		87	%
	Risk free interest rate		0.52	%
	Expected term (years)		5
	Dividend yield		0	%
Vyrix Pharmaceuticals [Member]	'
Stock Option Activity	'
	Vyrix stock option activity is as follows:
		Number of			Exercise Price			Weighted Average			Aggregate Fair
		Options						Remaining			Value
								Contractual Life
	Outstanding December 31, 2013		500,000		$	1.75			9.94		$	557,134
	Granted		450,000		$	0.7
	Exercised		—		$	—
	Forfeited/Cancelled		—		$	—
	Outstanding June 30, 2014		950,000		$	0.7			9.54		$	416,369
	Exercisable at June 30, 2014		237,500		$	0.7			9.54		$	104,092
	Available for grant at June 30, 2014		4,050,000
Assumptions Used in Computing Fair Value of All Options Granted	'
	As a result of the previous charge in the fourth quarter of 2013 and the revision of the exercise price, a reduction of stock compensation expense of $84,041 was reflected in the first quarter of 2014. Assumptions are as follows:
	Expected volatility	63% - 76%
	Risk free interest rate	0.90% - 2.02%
	Expected term (years)	5.0 - 6.5
	Dividend yield	0%

Basis_of_Presentation_Business2

Basis of Presentation, Business and Mergers - Additional Information (Detail) (USD $)

3 Months Ended

6 Months Ended

0 Months Ended

6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Mar. 23, 2011

Jun. 30, 2014

Mar. 15, 2013

Mar. 02, 2010

Jun. 30, 2014

Mar. 02, 2010

Apr. 16, 2009

BioSciences Merger [Member]

Luoxis Diagnostics [Member]

Luoxis Diagnostics [Member]

Chay Acquisitions [Member]

Life Sciences [Member]

Life Sciences [Member]

Life Sciences [Member]

Patent

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Non controlling interest, ownership percentage by parent

'

'

'

'

'

'

80.90%

'

'

'

95.70%

'

Increased general and administrative expenses

$662,397

$512,246

$1,271,656

$973,850

'

'

'

'

'

'

'

'

Date of incorporation Life Sciences in the state of Delaware

'

'

'

'

'

'

'

'

'

18-Dec-08

'

'

Common Stock, shares issued

51,937,431

'

51,937,431

'

42,065,031

'

'

4,652,500

'

'

'

3,500,000

Assets acquired, carrying value

'

'

'

'

'

'

'

'

'

'

'

0

Common Stock, shares issued

'

'

'

'

'

'

'

'

15,068,942

'

'

'

Issuance of additional common stock

'

'

'

'

'

'

'

'

1,325,000

'

'

'

Purchase of common stock from control shareholders

'

'

'

'

'

'

'

'

263,624

'

'

'

Payments for purchase of common stock from control shareholders

'

'

'

'

'

'

'

'

$150,000

'

'

'

Number of patents issued

'

'

'

'

'

32

'

'

'

'

'

'

Number of pending patent applications

'

'

'

'

'

31

'

'

'

'

'

'

Fixed_Assets_Schedule_of_Fixed

Fixed Assets - Schedule of Fixed Assets (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Less accumulated depreciation	($145,265)	($97,584)
Fixed assets, net	8,687,592	1,298,504
Manufacturing Facility/Clean Room - in progress [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Fixed assets, gross	8,318,299	1,000,843
Office furniture and equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Fixed assets, gross	206,029	116,088
Lab equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Fixed assets, gross	$308,529	$279,157

Formation_of_Subsidiary_Additi

Formation of Subsidiary - Additional Information (Detail) (USD $)

0 Months Ended

6 Months Ended

0 Months Ended

1 Months Ended

6 Months Ended

0 Months Ended

1 Months Ended

Mar. 15, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Mar. 15, 2013

Mar. 15, 2013

Mar. 15, 2013

31-May-13

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Mar. 15, 2013

31-May-13

Jun. 30, 2014

Trauma Research LLC [Member]

Placement Agent [Member]

Luoxis Diagnostics [Member]

Luoxis Diagnostics [Member]

Luoxis Diagnostics [Member]

Luoxis Diagnostics [Member]

Luoxis Diagnostics [Member]

Luoxis Diagnostics [Member]

Luoxis Diagnostics [Member]

Luoxis Diagnostics [Member]

Vyrix Pharmaceuticals [Member]

Majority Shareholder [Member]

Non-controlling Interest [Member]

Placement Agent [Member]

Placement Agent [Member]

Subsidiary or Equity Method Investee [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gross proceeds from private placement

'

$68,442,553

$143,519

'

'

'

$4,652,500

'

$0

$4,652,500

'

'

'

'

'

Private placement shares issued

'

51,937,431

'

42,065,031

'

'

4,652,500

'

'

'

'

'

'

'

'

Private placement per share

'

'

'

'

'

'

$1

'

'

'

'

'

'

'

'

Net proceeds from private placement

'

'

'

'

'

3,980,290

'

'

'

'

'

'

'

'

'

Warrants issued to placement agent

'

'

'

'

'

313,064

'

'

'

'

'

'

'

'

'

Warrants issued to placement agent, shares

'

'

'

'

'

465,250

'

465,250

'

'

'

'

'

'

'

Cash paid for assignment of all diagnostic patent

'

0

330,000

'

330,000

'

'

'

'

'

'

'

'

'

'

Shares issued for assignment of all diagnostic patent

'

'

'

'

'

'

'

'

'

'

'

'

50,000

'

'

Common stock value issued for assignment of all diagnostic patent

'

'

'

'

'

'

'

'

'

'

'

'

330,000

'

'

Warrant term

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'3 years 11 months 1 day

'

Exercise price of Warrant

'

'

'

'

'

$1

'

$1

'

'

'

'

'

'

'

Estimated useful life of patent

'15 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Non controlling interest, ownership percentage by parent

'

'

'

'

'

'

'

'

80.90%

'

80.90%

'

'

'

'

Non controlling interest, ownership percentage by noncontrolling owners

'

'

'

'

'

'

'

'

'

'

'

19.10%

'

'

'

Prepaid balance related to the potential offering cost

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$521,000

License_AgreementRevenue_Recog1

License Agreement/Revenue Recognition - Additional Information (Detail) (USD $)	6 Months Ended
	Jun. 30, 2014
Revenue Recognition [Line Items]	'
Upfront payment	$500,000
Net proceeds after withholding of Korean tax	417,500
Recognition period for license agreement effective date	'10 years
Milestone payments earned and recognized	3,200,000
Royalty percentage based on net sales	25.00%
Royalties earned to date	0
Vyrix Pharmaceuticals [Member]	'
Revenue Recognition [Line Items]	'
Recognition period for license agreement effective date	'7 years
Milestone payments earned and recognized	3,025,000
Amount paid by supplier	$250,000

Derivative_Financial_Instrumen1

Derivative Financial Instruments - Additional Information (Detail) (USD $)	3 Months Ended	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2013	Feb. 28, 2011
Derivative Instruments And Hedging Activities Disclosure [Abstract]	'	'	'
Senior Convertible Debentures were converted to common stock	'	'	1,281,852
Unrealized (gain) loss associated with warrants recorded at fair value	$139,389	$265,867	'

Commitments_and_Contingencies_1

Commitments and Contingencies - Summary of Commitments and Contingencies (Detail) (USD $)	Jun. 30, 2014	Oct. 31, 2013
Commitment And Contingencies [Line Items]	'	'
Total	$25,492,006	'
Remaining 2014	10,411,647	'
2015	3,450,445	'
2016	3,171,639	'
2017	3,181,312	'
2018	3,190,985	'
Thereafter	2,085,978	'
Manufacturing Facility/Clean Room - in progress [Member]	'	'
Commitment And Contingencies [Line Items]	'	'
Total	2,473,922	'
Remaining 2014	2,473,922	'
2015	0	'
2016	0	'
2017	0	'
2018	0	'
Thereafter	0	'
Ampion Supply Agreement [Member]	'	'
Commitment And Contingencies [Line Items]	'	'
Total	11,475,000	11,475,000
Remaining 2014	1,275,000	'
2015	2,550,000	'
2016	2,550,000	'
2017	2,550,000	'
2018	2,550,000	'
Thereafter	0	'
Clinical Research and Trial Obligations [Member]	'	'
Commitment And Contingencies [Line Items]	'	'
Total	6,709,007	'
Remaining 2014	6,420,528	'
2015	288,479	'
2016	0	'
2017	0	'
2018	0	'
Thereafter	0	'
Sponsored Research Agreement With Related Party [Member]	'	'
Commitment And Contingencies [Line Items]	'	'
Total	1,543,750	'
Remaining 2014	162,500	'
2015	325,000	'
2016	325,000	'
2017	325,000	'
2018	325,000	'
Thereafter	81,250	'
Office Lease [Member]	'	'
Commitment And Contingencies [Line Items]	'	'
Total	3,290,327	'
Remaining 2014	79,697	'
2015	286,966	'
2016	296,639	'
2017	306,312	'
2018	315,985	'
Thereafter	$2,004,728	'

Commitments_and_Contingencies_2

Commitments and Contingencies - Additional Information (Detail) (USD $)	6 Months Ended							6 Months Ended
	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Oct. 31, 2013	Jun. 30, 2014	Jun. 30, 2014
		Office Space [Member]	Newly Leased Office Space and Manufacturing Facility [Member]	After Amendment [Member]	Ampion Supply Agreement [Member]	Ampion Supply Agreement [Member]	Ampion Study Production [Member]	Optina study drug [Member]
							Clinical Research Obligations [Member]	Clinical Research Obligations [Member]
Commitments and Contingencies [Line Items]	'	'	'	'	'	'	'	'
Total commitment	$25,492,006	'	'	'	$11,475,000	$11,475,000	'	'
Commitment remain under terms of clinical research agreement	'	'	'	'	'	'	2,074,297	'
Remaining contract commitments related to study drug	'	'	'	'	'	'	'	4,634,710
Sponsored Research Agreement termination notice period	'180 days	'	'	'	'	'	'	'
Equipment lease payments net	263,750	'	'	325,000	'	'	'	'
Extend the termination date	'	'	'	31-Mar-19	'	'	'	'
Non-cancellable operating lease period	'	'	'125 months	'	'	'	'	'
Non-cancellable operating lease initiation date	'	20-May-11	13-Dec-13	'	'	'	'	'
Non-cancellable operating lease effective date	'	1-Jun-11	1-May-14	'	'	'	'	'
Non-cancellable operating lease expire date	31-Aug-14	31-Jul-14	'	'	'	'	'	'
Lease initial base rent per month	'	'	23,376	'	'	'	'	'
Total base rent over the term of the lease	'	'	$3,300,000	'	'	'	'	'

Commitments_and_Contingencies_3

Commitments and Contingencies - Rent Expense (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Commitments And Contingencies Disclosure [Abstract]	'	'	'	'
Rent expense	$92,183	$29,118	$122,136	$58,678

Common_Stock_Additional_Inform

Common Stock - Additional Information (Detail) (USD $)	6 Months Ended			0 Months Ended	1 Months Ended	0 Months Ended	1 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Dec. 26, 2013	Sep. 30, 2011	Mar. 05, 2014	Sep. 30, 2013
				Shelf Registration [Member]	Shelf Registration [Member]	Underwritten Public Offering [Member]	Registered Direct Placements [Member]
Components Of Common Stock [Line Items]	'	'	'	'	'	'	'
Common Stock, shares authorized	100,000,000	'	100,000,000	'	'	'	'
Common Stock, par value	$0.00	'	$0.00	'	'	$7	$5.50
Preferred Stock, shares authorized	10,000,000	'	10,000,000	'	'	'	'
Preferred Stock, par value	$0.00	'	$0.00	'	'	'	'
Common stock and warrants	'	'	'	$100,000,000	$80,000,000	'	'
Common stock to be sold by directors and management in future public offerings	'	'	'	1,500,000	1,000,000	'	'
Remaining common stocks and warrants under shelf registration	60,000,000	'	'	'	'	'	'
Common stock issued	51,937,431	'	42,065,031	'	'	9,775,000	4,600,319
Gross proceeds from issuance of common stock	68,442,553	143,519	'	'	'	68,425,000	'
Net proceeds from issuance of common stock	'	'	'	'	'	63,425,223	'
Gross proceeds from issuance of common stock	'	'	'	'	'	'	25,301,754
Net proceeds from issuance of common stock	'	'	'	'	'	'	$25,003,986

Equity_Instruments_Additional_

Equity Instruments - Additional Information (Detail) (USD $)

3 Months Ended

6 Months Ended

0 Months Ended

6 Months Ended

0 Months Ended

6 Months Ended

0 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

6 Months Ended

3 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Mar. 15, 2013

Jun. 30, 2014

Jun. 15, 2013

Jun. 15, 2013

Jun. 30, 2014

Jun. 15, 2013

Jun. 30, 2014

Dec. 31, 2013

Mar. 31, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

31-May-13

Jun. 30, 2014

Dec. 31, 2013

31-May-13

Placement Agent [Member]

Debt [Member]

Luoxis 2013 Plan [Member]

Luoxis 2013 Plan [Member]

Luoxis 2013 Plan [Member]

Luoxis 2013 Plan [Member]

Vyrix 2013 Plan [Member]

Vyrix 2013 Plan [Member]

Vyrix 2013 Plan [Member]

Vyrix 2013 Plan [Member]

Ampio March 2010 Stock Plan[Member]

Private Placement [Member]

Scenario, Adjustment [Member]

Luoxis Diagnostics [Member]

Luoxis Diagnostics [Member]

Luoxis Diagnostics [Member]

Luoxis Diagnostics [Member]

Luoxis 15 June 2013 Award [Member]

Luoxis First Quarter 2014 Award [Member]

Annual Vesting [Member]

Vyrix 18 Nov 2013 Award [Member]

Vyrix 18 Nov 2013 Award [Member]

Annual Vesting [Member]

Vyrix 2013 Plan [Member]

Placement Agent [Member]

Luoxis 15 June 2013 Award [Member]

Chief executive officer [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares of common stock reserved for issuance

'

'

'

'

'

'

5,000,000

'

'

'

5,000,000

'

'

'

11,700,000

'

'

'

'

'

'

Forfeiture rate

'

'

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares granted to chief executive officer

'

'

'

'

'

'

'

1,800,000

150,000

'

950,000

'

500,000

'

'

'

950,000

'

'

'

'

Fair value of stock options under Black-Scholes option pricing model

'

'

'

'

'

'

'

$1,272,366

$101,242

'

'

'

'

'

'

'

'

'

$1,373,607

$1,272,366

'

Exercise Price for Shares Granted

$1.60

'

'

'

'

'

'

$1

$1

'

'

'

$1.75

'

'

'

$0.70

'

$1

'

'

Percentage of Shares Vested

'

'

'

'

'

'

'

'

'

25.00%

'

'

'

25.00%

'

'

'

'

'

'

'

Vesting Period

'

'

'

'

'

'

'

'3 years

'3 years

'

'3 years

'

'

'

'

'

'

'

'

'

'

Number of shares vested

'

'

'

'

'

'

'

'

'

'

237,500

'

'

'

'

'

'

'

'

'

'

Reduction of stock compensation expense

1,605,674

772,324

2,656,905

1,458,853

'

'

'

'

'

'

'

140,070

'

'

'

'

84,041

'

'

'

'

Weighted average exercise price, warrants issued to debenture holders

'

'

'

'

'

$1.75

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants expiration date

'

'

'

'

'

31-Dec-13

'

'

'

'

'

'

'

'

'

31-Mar-16

'

'

'

'

'

Weighted average exercise price, warrants issued in connection with private placement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3.13

'

'

'

'

'

Warrants issued to placement agent, shares

'

'

'

'

465,250

'

'

'

'

'

'

'

'

'

'

'

'

465,250

'

'

'

Exercise price of Warrant

'

'

'

'

$1

'

'

'

'

'

'

'

'

'

'

'

'

$1

'

'

'

Warrant compensation from common stock offering costs

'

'

$0

$313,064

'

'

'

'

'

'

'

'

'

'

'

'

'

$313,064

'

'

'

Warrant term

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years 11 months 1 day

Equity_Instruments_Assumptions

Equity Instruments - Assumptions Used in Computing Fair Value of All Options Granted (Detail)	6 Months Ended
	Jun. 30, 2014
Schedule of Weighted Average Fair Values of Stock Options [Line Items]	'
Dividend yield	0.00%
Minimum [Member]	'
Schedule of Weighted Average Fair Values of Stock Options [Line Items]	'
Expected volatility	72.00%
Risk free interest rate	1.51%
Expected term (years)	'5 years
Maximum [Member]	'
Schedule of Weighted Average Fair Values of Stock Options [Line Items]	'
Expected volatility	85.00%
Risk free interest rate	2.27%
Expected term (years)	'7 years
Luoxis Diagnostics [Member]	'
Schedule of Weighted Average Fair Values of Stock Options [Line Items]	'
Expected volatility	87.00%
Dividend yield	0.00%
Luoxis Diagnostics [Member] | Stock Option [Member]	'
Schedule of Weighted Average Fair Values of Stock Options [Line Items]	'
Dividend yield	0.00%
Luoxis Diagnostics [Member] | Minimum [Member] | Stock Option [Member]	'
Schedule of Weighted Average Fair Values of Stock Options [Line Items]	'
Expected volatility	79.00%
Risk free interest rate	0.75%
Expected term (years)	'5 years
Luoxis Diagnostics [Member] | Maximum [Member] | Stock Option [Member]	'
Schedule of Weighted Average Fair Values of Stock Options [Line Items]	'
Expected volatility	82.00%
Risk free interest rate	1.38%
Expected term (years)	'6 years 6 months
Vyrix Pharmaceuticals [Member] | Stock Option [Member]	'
Schedule of Weighted Average Fair Values of Stock Options [Line Items]	'
Dividend yield	0.00%
Vyrix Pharmaceuticals [Member] | Minimum [Member] | Stock Option [Member]	'
Schedule of Weighted Average Fair Values of Stock Options [Line Items]	'
Expected volatility	63.00%
Risk free interest rate	0.90%
Expected term (years)	'5 years
Vyrix Pharmaceuticals [Member] | Maximum [Member] | Stock Option [Member]	'
Schedule of Weighted Average Fair Values of Stock Options [Line Items]	'
Expected volatility	76.00%
Risk free interest rate	2.02%
Expected term (years)	'6 years 6 months

Equity_Instruments_Ampio_Stock

Equity Instruments - Ampio Stock Option Activity (Detail) (USD $)	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2014	Dec. 31, 2013
		Ampio [Member]	Ampio [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Number of Options, Beginning Balance	'	5,135,058	'
Number of Options, Granted	'	570,000	'
Number of Options, Exercised	'	-107,504	'
Number of Options, Forfeited/Cancelled	'	-34,792	'
Number of Options, Ending Balance	'	5,562,762	5,135,058
Number of Options, Exercisable	'	4,070,518	'
Number of Options, Available for grant	'	4,796,092	'
Weighted Average Exercise Price, Beginning Balance	'	$3.54	'
Weighted Average Exercise Price, Granted	$1.60	$7.21	'
Weighted Average Exercise Price, Exercised	'	$1.57	'
Weighted Average Exercise Price, Forfeited/Cancelled	'	$3.42	'
Weighted Average Exercise Price, Ending Balance	'	$3.62	$3.54
Weighted average exercise price, Exercisable	'	$2.91	'
Weighted Average Remaining Contractual Life	'	'	'
Weighted Average Remaining Contractual Life, Outstanding	'	'7 years 8 months 27 days	'8 years 8 months 27 days
Weighted Average Remaining Contractual Life, Exercisable	'	'7 years 3 months 26 days	'
Aggregate Fair Value, Beginning Balance	'	$10,273,070	'
Aggregate Fair Value, Ending Balance	'	12,411,628	10,273,070
Aggregate Fair Value, Exercisable	'	$7,292,070	'

Equity_Instruments_Luoxis_Stoc

Equity Instruments - Luoxis Stock Option Activity (Detail) (USD $)	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2014	Dec. 31, 2013
		Luoxis Diagnostics [Member]	Luoxis Diagnostics [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Number of Options, Beginning Balance	'	1,800,000	'
Number of Options, Granted	'	150,000	'
Number of Options, Exercised	'	0	'
Number of Options, Forfeited/Cancelled	'	0	'
Number of Options, Ending Balance	'	1,950,000	1,800,000
Number of Options, Exercisable	'	937,500	'
Number of Options, Available for grant	'	3,050,000	'
Weighted Average Exercise Price, Beginning Balance	'	$1	'
Weighted Average Exercise Price, Granted	$1.60	$1	'
Weighted Average Exercise Price, Exercised	'	'	'
Weighted Average Exercise Price, Forfeited/Cancelled	'	'	'
Weighted Average Exercise Price, Ending Balance	'	$1	$1
Weighted average exercise price, Exercisable	'	$1	'
Weighted Average Remaining Contractual Life	'	'	'
Weighted Average Remaining Contractual Life, Outstanding	'	'9 years 4 days	'9 years 8 months 19 days
Weighted Average Remaining Contractual Life, Exercisable	'	'8 years 11 months 23 days	'
Aggregate Fair Value, Beginning Balance	'	$1,272,366	'
Aggregate Fair Value, Ending Balance	'	1,373,607	1,272,366
Aggregate Fair Value, Exercisable	'	$661,493	'

Equity_Instruments_Vyrix_Stock

Equity Instruments - Vyrix Stock Option Activity (Detail) (USD $)	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2014	Dec. 31, 2013
		Vyrix Pharmaceuticals [Member]	Vyrix Pharmaceuticals [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Number of Options, Beginning Balance	'	500,000	'
Number of Options, Granted	'	450,000	'
Number of Options, Exercised	'	0	'
Number of Options, Forfeited/Cancelled	'	0	'
Number of Options, Ending Balance	'	950,000	500,000
Number of Options, Exercisable	'	237,500	'
Number of Options, Available for grant	'	4,050,000	'
Weighted Average Exercise Price, Beginning Balance	'	$1.75	'
Weighted Average Exercise Price, Granted	$1.60	$0.70	'
Weighted Average Exercise Price, Exercised	'	'	'
Weighted Average Exercise Price, Forfeited/Cancelled	'	'	'
Weighted Average Exercise Price, Ending Balance	'	$0.70	$1.75
Weighted average exercise price, Exercisable	'	$0.70	'
Weighted Average Remaining Contractual Life, Outstanding	'	'9 years 6 months 15 days	'9 years 11 months 9 days
Weighted Average Remaining Contractual Life, Exercisable	'	'9 years 6 months 15 days	'
Aggregate Fair Value, Beginning Balance	'	$557,134	'
Aggregate Fair Value, Ending Balance	'	416,369	557,134
Aggregate Fair Value, Exercisable	'	$104,092	'

Equity_Instruments_Summary_of_

Equity Instruments - Summary of Stock-Based Compensation Expense (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation expenses	$1,605,674	$772,324	$2,656,905	$1,458,853
Ampio [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Unrecognized expense at June 30, 2014	4,102,852	'	'	'
Weighted average remaining years to vest	'1 year 3 months 29 days	'	'	'
Luoxis Diagnostics [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Unrecognized expense at June 30, 2014	698,425	'	'	'
Weighted average remaining years to vest	'2 years 11 days	'	'	'
Vyrix Pharmaceuticals [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Unrecognized expense at June 30, 2014	275,193	'	'	'
Weighted average remaining years to vest	'2 years 6 months 15 days	'	'	'
Research and Development Expenses [Member] | Stock Options [Member] | Ampio [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation expenses	399,266	223,680	1,037,698	378,371
Research and Development Expenses [Member] | Stock Options [Member] | Luoxis Diagnostics [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation expenses	51,584	202,495	103,168	202,495
Research and Development Expenses [Member] | Stock Options [Member] | Vyrix Pharmaceuticals [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation expenses	8,454	'	37,605	'
General and Administrative Expenses [Member] | Stock Options [Member] | Ampio [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation expenses	1,092,060	231,695	1,391,067	675,483
General and Administrative Expenses [Member] | Stock Options [Member] | Luoxis Diagnostics [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation expenses	35,576	114,454	93,591	114,454
General and Administrative Expenses [Member] | Stock Options [Member] | Vyrix Pharmaceuticals [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation expenses	18,734	'	-36,224	'
General and Administrative Expenses [Member] | Common Stock Issued for Services [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation expenses	'	'	$30,000	$88,050

Equity_Instruments_Warrants_Is

Equity Instruments - Warrants Issued in Conjunction with its Senior Convertible Debentures (Detail) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Number of Warrants Outstanding	'	'
Number of Warrants Outstanding, Beginning Balance	527,690	'
Number of Warrants Outstanding, Ending Balance	516,329	527,690
Weighted Average Exercise Price, Warrants	'	'
Weighted Average Exercise Price, Outstanding Beginning Balance	$2.93	'
Weighted Average Exercise Price, Outstanding Ending Balance	$3.26	$2.93
Weighted Average Remaining Contractual Life, Warrants	'	'
Weighted Average Remaining Contractual Life, Warrants Outstanding	'1 year 11 months 9 days	'2 years 5 months 9 days
Registered Direct Placements [Member]	'	'
Number of Warrants Outstanding	'	'
Number of Warrants exercised - Private/Registered Direct Placements	-11,261	'
Weighted Average Exercise Price, Warrants	'	'
Weighted Average Exercise Price, Warrants exercised - Private/Registered Direct Placements	($3.13)	'
Registered Direct Placement One [Member]	'	'
Number of Warrants Outstanding	'	'
Number of Warrants exercised - Private/Registered Direct Placements	-100	'
Weighted Average Exercise Price, Warrants	'	'
Weighted Average Exercise Price, Warrants exercised - Private/Registered Direct Placements	($4.06)	'

Equity_Instruments_Significant

Equity Instruments - Significant Assumptions (Detail)	6 Months Ended
	Jun. 30, 2014
Assumptions used to Determine Fair Value Options [Line Items]	'
Dividend yield	0.00%
Luoxis Diagnostics [Member]	'
Assumptions used to Determine Fair Value Options [Line Items]	'
Expected volatility	87.00%
Risk free interest rate	0.52%
Expected term (years)	'5 years
Dividend yield	0.00%

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)

3 Months Ended

6 Months Ended

3 Months Ended

12 Months Ended

6 Months Ended

0 Months Ended

3 Months Ended

12 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2014

Sep. 30, 2014

Dec. 31, 2014

Jun. 30, 2014

Jun. 30, 2014

Sep. 30, 2013

Mar. 02, 2010

Mar. 31, 2012

Dec. 31, 2011

Sponsored Research Agreement With Related Party [Member]

After Amendment [Member]

Luoxis Diagnostics [Member]

Luoxis Diagnostics [Member]

Luoxis Diagnostics [Member]

Luoxis Diagnostics [Member]

Luoxis Diagnostics [Member]

Luoxis Diagnostics [Member]

Luoxis Diagnostics [Member]

Life Sciences [Member]

Life Sciences [Member]

Life Sciences [Member]

Scenario, Plan [Member]

Scenario, Plan [Member]

Scenario, Plan [Member]

Scenario, Plan [Member]

Scenario, Plan [Member]

Management [Member]

Management [Member]

Management [Member]

First Installment [Member]

Second Installment [Member]

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Description of leasing arrangements

'

'

'Under the terms of the research agreement, Ampio is to provide personnel and equipment with an equivalent value of $263,750 per year and to make monthly equipment lease payments of $7,236 on behalf of TRLLC. Lease commitments expired as of January 2011.

'

'

'

'

'

'

'

'

'

'

'

'

'

Equipment lease payments net

$263,750

'

$263,750

'

'

$325,000

'

'

'

'

'

'

'

'

'

'

Monthly equipment lease payments

'

'

7,236

'

'

'

'

'

'

'

'

'

'

'

'

'

Lease expiration date

'

'

31-Aug-14

'

'

'

'

'

'

'

'

'

'

'

'

'

Consideration for services related to research and development

'

'

-1,340,000

'

'

'

890,000

150,000

300,000

1,340,000

725,000

615,000

'

'

'

'

Amortization of prepaid expense

'

'

77,521

'

'

'

'

'

'

'

'

'

'

'

'

'

Contract term

'

'

'60 months 15 days

'

'

'

'

'

'

'

'

'

'

'

'

'

Extend the termination date

'

'

'

'

'

31-Mar-19

'

'

'

'

'

'

'

'

'

'

Monthly consideration for services related to research and development

5,567,559

4,736,950

13,361,967

7,062,168

5,834

'

'

'

'

'

'

'

'

'

'

'

Additional amount paid to related party

'

'

'

'

'

'

'

'

'

'

'

'

2,000

'

'

'

Subscriptions for aggregate shares of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

1,325,000

'

'

Purchase price for aggregate shares of common stock

'

'

63,425,223

'

'

'

'

'

'

'

'

'

'

150,183

'

'

Repayment of advance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$36,883

$22,660

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (USD $)	3 Months Ended	0 Months Ended
	Jun. 30, 2014	Jul. 16, 2014
		Subsequent Event [Member]
Subsequent Event [Line Items]	'	'
Options awarded to advisors and employees	'	885,000
Common stock awarded, exercise price	$1.60	'